WuXi Biologics (Cayman) Management

Management criteria checks 2/4

WuXi Biologics (Cayman)'s CEO is Chris Chen, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is CN¥96.91M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth HK$207.15M. The average tenure of the management team and the board of directors is 2.6 years and 7.2 years respectively.

Key information

Chris Chen

Chief executive officer

CN¥96.9m

Total compensation

CEO salary percentage	4.1%
CEO tenure	8.8yrs
CEO ownership	0.4%
Management average tenure	2.6yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Chen's remuneration changed compared to WuXi Biologics (Cayman)'s earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensation vs Market: Chris's total compensation ($USD13.39M) is above average for companies of similar size in the Hong Kong market ($USD887.93K).

Compensation vs Earnings: Chris's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Chris Chen (51 yo)

8.8yrs

Tenure

CN¥96,911,000

Compensation

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ge Li	Founder & Chairman	10.8yrs	no data	no data
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% HK$ 207.2m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% HK$ 7.9m
Ming Tu	CFO & Executive VP	3yrs	no data	no data
Lihua Yu	COO & Senior VP	less than a year	no data	no data
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	no data	no data
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	no data	no data
Lina Fan	Senior VP & Head of Investor Relations	less than a year	no data	no data
He Wang	Chief Compliance Officer	2.2yrs	no data	no data
Li Xiong	VP & Head of Global Human Resources	no data	no data	no data
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	no data	no data
Keqiang Shen	Chief Digital Officer	4.8yrs	no data	no data

2.6yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 2269's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ge Li	Founder & Chairman	10.8yrs	no data	no data
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% HK$ 207.2m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% HK$ 7.9m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% HK$ 369.8k
James Larrick	Member of Scientific Advisory Board	6.8yrs	no data	no data
David D. Ho	Member of Scientific Advisory Board	6.8yrs	no data	no data
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	no data	no data
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	no data	no data
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% HK$ 311.1k
Yanling Cao	Non-Executive Director	8.5yrs	no data	no data
Yibing Wu	Non-Executive Director	8.5yrs	no data	no data
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% HK$ 2.9m

7.2yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 2269's board of directors are considered experienced (7.2 years average tenure).

WuXi Biologics (Cayman) Management

Management criteria checks 2/4

Key information

Recent management updates

CEO & Executive Director recently sold HK$6.6m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week